The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

Nature

Volumn 507, Issue 7493, 2014, Pages 508-512

  Paolino, Magdalena ^a   Choidas, Axel ^b   Wallner, Stephanie ^c   Pranjic, Blanka ^a   Uribesalgo, Iris ^a   Loeser, Stefanie ^a   Jamieson, Amanda M ^d   Langdon, Wallace Y ^e   Ikeda, Fumiyo ^a   Fededa, Juan Pablo ^a   Cronin, Shane J ^a   Nitsch, Roberto ^a   Schultz Fademrecht, Carsten ^b   Eickhoff, Jan ^b   Menninger, Sascha ^b   Unger, Anke ^b   Torka, Robert ^f   Gruber, Thomas ^c   Hinterleitner, Reinhard ^c   Baier, Gottfried ^c   Wolf, Dominik ^c,g   Ullrich, Axel ^f   Klebl, Bert M ^b   Penninger, Josef M ^a   more..

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b Lead Discovery Center GmbH   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f Max Planck Institute   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LDC 1267; PROTEIN TYROSINE KINASE INHIBITOR; TAM RECEPTOR; TYROSINE KINASE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 CASITAS B LINEAGE LYMPHOMA B; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT; DISEASE CONTROL; ENZYME ACTIVITY; HEALTH CARE; IMMUNE SYSTEM; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL ACTIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE DELETION; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; UBIQUITINATION;

MURINAE; MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTICOAGULANTS; FEMALE; KILLER CELLS, NATURAL; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR PROTEIN-TYROSINE KINASES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; WARFARIN;

EID: 84897954522     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12998     Document Type: Article

References (38)

1. Brabletz, T., Lyden, D., Steeg, P. S. & Werb, Z. Roadblocks to translational advances on metastasis research. Nature Med. 19, 1104-1109 (2013).
2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
3. Lacour, F., Oberling, C. & Guerin, M. Effect of dicoumarol on the development of metastases of the T8 epithelioma in the rat; new research. Bull. Assoc. Fr. Etud. Cancer 44, 88-91 (1957).
4. Loeser, S. et al. Spontaneous tumor rejection by cbl-b-deficient CD81 T cells. J. Exp. Med. 204, 879-891 (2007).
5. Chiang, J.Y., Jang, I.K., Hodes, R.&Gu, H. Ablation of Cbl-bprovidesprotectionagainst transplanted and spontaneous tumors. J. Clin. Invest. 117, 1029-1036 (2007).
6. Paolino, M. et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. J. Immunol. 186, 2138-2147 (2011).
7. Oksvold, M. P., Dagger, S. A., Thien, C. B. & Langdon, W. Y. The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgEactivated mast cells. Mol. Immunol. 45, 925-936 (2008).
8. Kojo, S. et al. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination ofCARMA1. Proc.NatlAcad. Sci.USA106, 17847-17851 (2009).
9. Makino, Y., Kanno, R., Ito, T., Higashino, K.&Taniguchi, M. Predominant expression of invariant Va141 TCR a chain in NK1.11 T cell populations. Int. Immunol. 7, 1157-1161 (1995).
10. Pannellini, T., Forni, G.&Musiani, P. Immunobiology of her-2/neu transgenic mice. Breast Dis. 20, 33-42 (2004).
11. Linger, R. M., Keating, A. K., Earp, H. S. & Graham, D. K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35-83 (2008).
12. Nagata, K. et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J. Biol. Chem. 271, 30022-30027 (1996).
13. Caraux, A. et al. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nature Immunol. 7, 747-754 (2006).
14. Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nature Rev. Immunol. 8, 327-336 (2008).
15. Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 20, Unit 20 22 (2001).
16. Pirmohamed, M. Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharmacol. 62, 509-511 (2006).
17. Ryan, J. J., Ketcham, A. S. & Wexler, H. Reduced incidence of spontaneous metastases with long-term Coumadin therapy. Ann. Surg. 168, 163-168 (1968).
18. McCulloch, P. & George, W. D. Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br. J. Cancer 59, 179-183 (1989).
19. Brown, J. M. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res. 33, 1217-1224 (1973).
20. Hasanbasic, I., Rajotte, I. & Blostein, M. The role of c-carboxylation in the antiapoptotic function of gas6. J. Thromb. Haemost. 3, 2790-2797 (2005).
21. Yanagita, M. et al. Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am. J. Pathol. 158, 1423-1432 (2001).
22. Nagai, K. et al.Growtharrest-specific gene6is involved in glomerular hypertrophyin the early stage of diabetic nephropathy. J. Biol. Chem. 278,18229-18234(2003).
23. Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306-311 (2001).
24. Haglund, K. & Dikic, I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J. Cell Sci. 125, 265-275 (2012).
25. Valverde, P. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem. Biophys. Res. Commun. 333, 180-185 (2005).
26. Caspi, R. R. Immunotherapy of autoimmunity and cancer: the penalty for success. Nature Rev. Immunol. 8, 970-976 (2008).
27. Bachmaier, K. et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211-216 (2000).
28. Lee-MacAry, A. E. et al. Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. J. Immunol. Methods 252, 83-92 (2001).
29. Cerwenka, A., Baron, J. L. & Lanier, L. L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl Acad. Sci. USA 98, 11521-11526 (2001).
30. Harshan, K. V. & Gangadharam, P. R. In vivo depletion of natural killer cell activity leads to enhancedmultiplication ofMycobacteriumaviumcomplex in mice. Infect. Immun. 59, 2818-2821 (1991).
31. Jamieson, A. M. et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19-29 (2002).
32. Carlyle, J. R. et al. Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. J. Immunol. 176, 7511-7524 (2006).
33. Kasai, M. et al. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 291, 334-335 (1981).
34. Walzer, T. et al. Identification, activation, and selective in vivo ablation ofmouse NK cells via NKp46. Proc. Natl Acad. Sci. USA 104, 3384-3389 (2007).
35. Roepstorff, K. et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10, 1115-1127 (2009).
36. Schultz-Fademrecht, C. a. Pharmaceutically active compounds as Axl inhibitors. European patent 2423208 A1. (2012).
37. Godl, K. et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 100, 15434-15439 (2003).
38. Brehmer, D., Godl, K., Zech, B., Wissing, J. & Daub, H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell Proteomics, 3, 490-500 (2004).